Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Etanercept Biosimilar SB4 a Cost-Effective Alternative for Psoriasis, PsA

Key clinical point: The drug’s approval provides a considerable opportunity to lower cost of treatment and expand treatment options.

Major finding: Results achieved following 24-week intermittent treatment regimen.

Study details: Letter to the editor; 40 patients evaluated in observational, retrospective, single-center study.

Disclosures: The authors reported serving as consultants and speakers for AbbVie, Biogen, Eli Lilly, Janssen, Pfizer, and Novartis.

Citation:

Giunta A et al. Br J Dermatol. 2019 May 3. doi: 10.1111/bjd.18090.